



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

**Thiopurine S- methyltransferase
genotype mutation in pediatric patients
with inflammatory bowel disease on
azathioprine: A pilot study**

Thesis

Submitted For partial Fulfillment of
MD Degree in Pediatrics

By

Nada Atef Abd El-Hafez

M.B.B.CH(2008) M.Sc(2013)

Faculty of Medicine - Ain Shams Univeristy

Under Supervision of

Prof. Dr. Mostafa Abd Al-Aziz El-Hodhod

Professor of Pediatrics

Faculty of Medicine - Ain Shams Univeristy

Dr.Marwa Talaat El-Deeb

Assistant Professor of Pediatrics

Faculty of Medicine - Ain Shams Univeristy

Dr.Yosra Mohamed Mohsen

Lecturer of Pediatrics

Faculty of Medicine - Ain shams Univeristy

Dr.Nora Nassef Abd El-Gawad

Molecular Genetics Researcher

Molecular Genetics and Enzymology Dep.

National Research Centre

Faculty of Medicine - Ain Shams Univeristy

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سببنا انك لا تعلم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٢٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mostafa Abd El Aziz El Hodhod**, Head of Pediatrics department, Faculty of medicine- Ain Shams University for keen guidance, kind supervision, valuable advice and continuous encouragement his which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Marwa Talaat El deeb**, Professor of Pediatrics Faculty of medicine- Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I wish to introduce my deep respect and thanks to **Dr. Yosra Mohamed Mohsen**, Lecturer of Pediatrics, Faculty of Medicine, Ain shams Univeristy for her great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Nora Nassef Abd El-Gawad**, Molecular genetics Researcher, Molecular genetics and enzymology Dep., National research center for her kindness and supervision.*

*Special thanks to **Prof. Dr. Ahmad Mohamed Hamdy**, head of gastroenterology department, ain shams university, and the whole gastroenterology team work, **Dr Dina Abdel Hamid**, **Dr Heba Amin** and **Dr Dina Heidar** for their support and encouragement.*

Last but not least my sincere thanks and appreciation to all patients participated in this study from GIT clinic, Children Hospital, Ain shams University.

Dedication

*I dedicate my dissertation work to the sake of **Allah**, my Creator and my Master,*

*My great teacher and messenger, prophet **Mohammed** (May Allah bless and grant him), who taught us the purpose of life*

*My family, friends and professors. A special feeling of gratitude to my loving **parents**, whose words of encouragement and push for tenacity ring in my ears.*

*My brother **Mohammed** who stands by me when things look bleak. I also dedicate this dissertation to my **husband** who leads me through the valley of darkness with light of hope and support. I will always appreciate all they have done, I dedicate this work and give special thanks to my best friend **Sara. Kinda**, my wonderful daughter with her secure hugs, All the people in my life who touch my heart, I dedicate this research.*

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations.....	vi
Introduction	1
Aim of the Work.....	3
Review of Literature	
Inflammatory Bowel Disease	4
Thiopurine Drugs.....	61
Patients and Methods.....	88
Results	120
Discussion	161
Summary	184
Conclusion	187
Recommendations	188
References	189
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Interleukins involved in IBD pathogenesis	12
Table (2):	Genes related to IBD disease activity.....	18
Table (3):	Differences in the macroscopic appearance between Crohn's disease and ulcerative colitis.....	32
Table (4):	Shows the macroscopic differences between UC and Crohn's disease.....	32
Table (5):	Microscopic differences between crohn's and ulcerative colitis:.....	36
Table (6):	Comparison between Montreal and Paris classification for ulcerative colitis:	50
Table (7):	Comparison between Montreal and Paris classification for Crohn's disease:	50
Table (8):	TPMT phenotypes and the therapeutic recommendations for azathioprine therapy, adapted from CPIC.....	86
Table (9):	Worldwide distribution of the most common TMPT alleles in healthy subjects in different ethnic groups and countries	87
Table (10):	Reagents for DNA extraction:.....	97
Table (11):	Primers for PCR:.....	102
Table (12):	Reagents used for PCR.....	102
Table (13):	Steps of DNA thermal cyclers.	103
Table (14):	Reagents for purification:	107
Table (15):	Sum of PUCAI (0-85)	117
Table (16):	Modified Pediatric Crohn's disease Activity Index	118
Table (17):	Descriptive data of all patients regarding sex, age and family history.	122
Table (18):	Descriptive data of all patients as regard anthropometric measures.	123

List of Tables (Cont...)

Table No.	Title	Page No.
Table (19):	Initial diagnostic labs for all IBD patients.....	124
Table (20):	Presenting symptoms in patient groups.	126
Table (21):	Growth parameters in patients' groups.	128
Table (22):	Initial examination signs in both groups:.....	129
Table (23):	Initial labs of patients of both groups.....	131
Table (24):	Endoscopic macroscopic and microscopic findings in both groups.	134
Table (25):	Drugs used in the two groups.....	136
Table (26):	Baseline activity score index in both groups.....	137
Table (27):	Comparison of ulcerative colitis activity at (0) month and 7 months.....	138
Table (28):	Remission and flare in both groups after 7 months.....	142
Table (29):	Labs follow up at 7 month in both groups.	146
Table (30):	Labs follow up between initial and at 7 month in crohn's patients.....	150
Table (31):	Labs follow up between initial and at 7 month in ulcerative colitis patients.....	153
Table (32):	Labs follow up at 0 month and 7 months for AZA side effects detection in two groups.....	156
Table (33):	Myelosuppression follow up in patient groups.....	157
Table (34):	Results of TPMT variants for all IBD patients.....	158
Table (35):	Side effects of azathioprine in relation to TPMT variants.....	160

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Algorithm of IBD pathophysiology	6
Figure (2):	Interaction between IBD different factors	7
Figure (3):	Inflammatory bowel disease (IBD) loci, represented by lead gene name, according to pathway	9
Figure (4):	Shows relation between genetic factors and phenotyping.....	11
Figure (5):	Shows the extra intestinal manifestations occurring in IBD	28
Figure (6):	Deep ulcers, sub mucosal oedema and haemorrhages in the sigmoid colon in a patient with Crohn's colitis.....	30
Figure (7):	Shows Multiple linear, deep ulcers with normal islands of intervening mucosa in the terminal ileum indicates severe Crohn's disease	30
Figure (8):	Endoscopic image of ulcerative colitis affecting the left side of the colon. The image shows confluent superficial ulceration and loss of mucosal architecture.	31
Figure (9):	Endoscopic image of a colon affected by ulcerative colitis	31
Figure (10):	Architectural distortion is a feature of chronic injury	33
Figure (11):	The acute, neutrophilic component of inflammation is graded as activity.....	34
Figure (12):	Inflammation in UC is limited to the mucosa and superficial submucosa	34
Figure (13):	CD may occur anywhere in the gastrointestinal tract.....	35

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (14):	Shows Inflammation in CD may be transmural.....	35
Figure (15):	Patients with inflammatory bowel disease have an increased risk of developing premalignant, dysplastic epithelial lesions.....	36
Figure (16):	Barium enema study showing narrowing in the small bowel from Crohn's Disease.....	38
Figure (17):	Shows Barium enema show tubular narrowing of the rectum and sigmoid colon with an abrupt transition zone.....	39
Figure (18):	Shows ulcerative colitis with pseudopolypoidosis and "backwash ileitis".....	39
Figure (19):	Shows Cobblestoning in Crohn disease.....	40
Figure (20):	Shows crohn disease involving the terminal ileum. Note the "string sign" in the right lower quadrant.....	41
Figure (21):	Shows an algorithm for treatment of crohns disease.....	56
Figure (22):	Shows an algorithm for treatment of ulcerative colitis	57
Figure (23):	Mechanism of action.....	62
Figure (24):	Metabolism of AZA	64
Figure (25):	Schematic outline of thiopurine metabolism	81
Figure (26):	Locates on chromosome 6 (6p22.3).....	82
Figure (27):	Shows thiopurine s -methyl transferase enzyme.....	83
Figure (28):	DNA Exaction Kit	96
Figure (29):	Shows a schematic diagram of the procedure.	99
Figure (30):	iNtRON-Kore Cat.No.25027	100
Figure (31):	Taq DNA polymerase	101

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (32):	Agarose gel.....	104
Figure (33):	1x TBE (Tris- borate- EDTA) buffer (pH 8.3).....	104
Figure (34):	Ethidium bromide (10 mg/ml).....	105
Figure (35):	PCR Marker (100 bp Ladder).....	105
Figure (36):	DNA dye (6 x DNA loading).....	105
Figure (37):	QIAquick PCR purification kit.....	106
Figure (38):	Wash buffer, buffer PB and elution buffer.....	107
Figure (39):	BigDye sequencing kit	110
Figure (40):	Crohn's (57.9%) & Ulcerative colitis (42.1%)	120
Figure (41):	Female (52.6%) & male (47.4%) in all IBD patients.....	122
Figure (42):	Presenting symptoms in patient groups.....	127
Figure (43):	Initial examination signs in both groups.....	130
Figure (44):	Pediatric ulcerative colitis activity index (PUCAI) remission and flare at initially and after 7 months follow up.....	138
Figure (45):	PUCAI at (0) month &(7) months follow up.....	139
Figure (46):	Crohn's disease remission and flare after 7 months follow up.....	140
Figure (47):	Crohn's disease activity index between (0)&(7) months.....	141
Figure (48):	Activity score of both groups at 0 month and 7 months.....	142
Figure (49):	Liver function tests initially & 7 months in both patient groups.....	149
Figure (50):	TPMT *3A, *3C, *2,B,4A genotyping sequencing chromatography.....	159

List of Abbreviations

Abb.	Full term
<i>6-MMP</i>	<i>6-Mercaptopurine</i>
<i>6MP</i>	<i>6-Mercaptopurine</i>
<i>ACCA</i>	<i>Antichitobioside carbohydrate IgA.</i>
<i>ADA</i>	<i>Adalimumab</i>
<i>ALCA</i>	<i>Anti laminaribioside carbohydrate IgG</i>
<i>ALT</i>	<i>Alanine transaminase</i>
<i>AMCA</i>	<i>Anti-synthetic mannoside antibodies.</i>
<i>ANC</i>	<i>Absolute neutrophilic count</i>
<i>ANCA</i>	<i>Antineutrophil cytoplasmic antibodies.</i>
<i>Anti-C</i>	<i>Anti-chitin</i>
<i>Anti-L</i>	<i>Anti-laminarin</i>
<i>Anti-OmpC</i>	<i>Antibodies to outer membrane porin C</i>
<i>APC</i>	<i>Antigen presenting cells.</i>
<i>ASA</i>	<i>Amino salicylic acid</i>
<i>ASCA</i>	<i>Anti-Saccharomyces cerevisiae antibodies</i>
<i>AST</i>	<i>Aspartate transaminase</i>
<i>ATG</i>	<i>Autology related Gene</i>
<i>BMI</i>	<i>Body mass index.</i>
<i>C14orf119</i>	<i>Chromosome 14 Open Reading Frame 119</i>
<i>CARD</i>	<i>Caspase activation and recruitment domains</i>
<i>CBC</i>	<i>Complete blood picture</i>
<i>CCR</i>	<i>Cassette chromosome recombinases</i>
<i>CD</i>	<i>Crohn's disease</i>
<i>CDH</i>	<i>Cellobiose dehydrogenase</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>CPEB</i>	<i>Cytoplasmic polyadenylation element binding protein</i>
<i>CREM</i>	<i>cAMP responsive element modulator</i>
<i>CRP</i>	<i>C-reactive protein</i>
<i>DAP</i>	<i>Death-associated protein</i>
<i>DNA</i>	<i>Deoxyribonucleic acid</i>
<i>DNMT3A</i>	<i>The DNA methyltransferase 3A</i>
<i>DRP</i>	<i>Dynamin-related protein</i>
<i>ECCO</i>	<i>European Crohn's and Colitis Organization</i>
<i>ECM</i>	<i>Extracellular matrix</i>
<i>ECM1</i>	<i>Extracellular matrix protein 1</i>
<i>EDTA</i>	<i>Ethylenediaminetetraacetic acid</i>
<i>EEN</i>	<i>Exclusive Enteral Nutrition</i>
<i>ERAP</i>	<i>The endoplasmic reticulum aminopeptidases</i>
<i>ESPGHAN</i>	<i>The European Society for Paediatric Gastroenterology Hepatology and Nutrition</i>
<i>ESR</i>	<i>Erythrocyte sedimentation rate</i>
<i>FADS</i>	<i>Flavin adenine dinucleotide (FAD)-binding proteins</i>
<i>FC</i>	<i>Fecal calprotectin.</i>
<i>FDFT1</i>	<i>Farnesyl-Diphosphate Farnesyltransferase</i>
<i>FGCR2A</i>	<i>Fc fragment of IgG receptor IIa</i>
<i>FL</i>	<i>Fecal lactoferrin.</i>
<i>GCKR</i>	<i>The glucokinase regulatory protein</i>
<i>GI</i>	<i>Gastro intestinal.</i>
<i>GMPR2</i>	<i>Guanosine Monophosphate Reductase</i>